De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months

Dialing Back M for Monoclonal: Successful De-escalation of Dose-Intensified Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

“…In a single-center retrospective study, Little et al [5] report on outcomes of de-escalation of 25 patients (20 Crohn's disease and 5 ulcerative colitis) treated with doseintensified anti-TNF therapy (infliximab 5 mg/kg 6 weekly or adalimumab 40 mg weekly) for 7-27 months. Prior to de-escalation, cases were discussed at a virtual IBD multidisciplinary meeting including IBD specialists, IBD nurse practitioners, and a pharmacist.…”